Research ArticleArticle
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials
Iain B. McInnes, Lluís Puig, Alice B. Gottlieb, Christopher T. Ritchlin, Michael Song, Yin You, Shelly Kafka, G. James Morgan, Proton Rahman and Arthur Kavanaugh for the PSUMMIT 1 and 2 Study Groups
The Journal of Rheumatology April 2019, jrheum.180792; DOI: https://doi.org/10.3899/jrheum.180792
Iain B. McInnes
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
Lluís Puig
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
Alice B. Gottlieb
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
Christopher T. Ritchlin
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
Michael Song
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
Yin You
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
Shelly Kafka
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
G. James Morgan
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
Proton Rahman
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
Arthur Kavanaugh
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab. IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson. I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego. Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk. Accepted for publication March 19, 2019.
Article Information
jrheum.180792
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online July 15, 2019.
Article Versions
- Latest version (April 1, 2019 - 04:00).
- You are currently viewing a Latest version of this article (July 15, 2019 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2019 The Journal of Rheumatology
Author Information
- Iain B. McInnes,
- Lluís Puig,
- Alice B. Gottlieb,
- Christopher T. Ritchlin,
- Michael Song,
- Yin You,
- Shelly Kafka,
- G. James Morgan,
- Proton Rahman and
- Arthur Kavanaugh; for the PSUMMIT 1 and 2 Study Groups
- From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA. This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab.
IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson.
I.B. McInnes, MD, PhD, University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre; L. Puig, MD, PhD, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona; A.B. Gottlieb, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai; C.T. Ritchlin, MD, MPH, University of Rochester, Medical Center; M. Song, MD, Janssen Research & Development LLC; Y. You, MS, Janssen Research & Development LLC; S. Kafka, MD, Janssen Scientific Affairs LLC; G.J. Morgan, MD, Janssen Scientific Affairs LLC; P. Rahman, MD, Memorial University; A. Kavanaugh, MD, University of California- San Diego.
Address correspondence to Dr. I.B. McInnes, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Level 4, 120 University Place, Glasgow, Scotland G12 8TA, UK. E-mail: Iain.McInnes@glasgow.ac.uk.
Accepted for publication March 19, 2019.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials
Iain B. McInnes, Lluís Puig, Alice B. Gottlieb, Christopher T. Ritchlin, Michael Song, Yin You, Shelly Kafka, G. James Morgan, Proton Rahman, Arthur Kavanaugh
The Journal of Rheumatology Apr 2019, jrheum.180792; DOI: 10.3899/jrheum.180792
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials
Iain B. McInnes, Lluís Puig, Alice B. Gottlieb, Christopher T. Ritchlin, Michael Song, Yin You, Shelly Kafka, G. James Morgan, Proton Rahman, Arthur Kavanaugh
The Journal of Rheumatology Apr 2019, jrheum.180792; DOI: 10.3899/jrheum.180792